Pulmonx achieved worldwide revenue of $23.9 million in Q2 2025, a 15% increase year-over-year, driven by strong international performance. Despite this growth, the company revised its full-year revenue guidance downwards due to slower-than-expected revenue conversion from U.S. initiatives, while also reducing its operating expense outlook.
Worldwide revenue reached $23.9 million in Q2 2025, marking a 15% increase compared to the same period last year.
International revenue grew significantly by 32% year-over-year to $9.1 million, providing a solid foundation for the quarter.
Gross margin for the second quarter of 2025 was 72%, a slight decrease from 74% in the prior year.
The company reported a net loss of $15.2 million, or $0.38 per share, and an Adjusted EBITDA loss of $8.4 million.
Pulmonx has revised its full-year 2025 revenue guidance downwards to a range of $90 million to $92 million, from previous expectations of $96 million to $98 million. However, the company also reduced its total operating expense guidance for the full year to $128 million to $130 million, down from $133 million to $135 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance